Shares of Sun Pharmaceutical Industries rose by over 5 percent in early trading on Monday following the company’s announcement of a significant acquisition of US-based Organon & Co., valued at $11.75 billion. This acquisition constitutes the largest overseas purchase by the Indian pharmaceutical company and the broader domestic industry.
At 9:38 am, Sun Pharma’s stock was priced at ₹1,698.90 on the National Stock Exchange, having peaked at an intraday high of ₹1,709, compared to the prior close of ₹1,620.40. This substantial increase highlights strong investor confidence in light of the all-cash deal.
As per the agreement, Sun Pharma will acquire all outstanding shares of Organon at a price of $14 per share. This acquisition is expected to significantly enhance the company’s global presence and bolster its standing in key therapeutic areas, especially within the US market.
Market analysts regard this acquisition as a strategic initiative that could foster long-term growth for Sun Pharma. However, stakeholders will closely monitor the execution and integration of the deal, as well as its effects on future earnings.
Published on April 27, 2026.
